{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:38:03Z","timestamp":1764333483054,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Despite different etiopathogenesis, Fabry Disease cardiomyopathy (FDc) and sarcomeric hypertrophic cardiomyopathy (HCM) share a similar hypertrophic phenotype, including anomalies of the mitral valve apparatus (AMVA). Some of these anomalies have also been described in the pre-hypertrophic stage of both diseases. This cardiovascular magnetic resonance (CMR) study aimed to: (i) compare AMVA between FDc and HCM with a similar degree of left ventricular hypertrophy (LVH), to add new insights into differential diagnosis; (ii) assess whether AMVA represent an early and progressive alteration in FDc; (iii) propose simple and potentially reproducible measurements of AMVA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational, retrospective study enrolled: (i) 80 Fabry patients, divided into three groups with increasing severity of cardiac phenotype (20 patients LVH-\/normal T1, 20 patients LVH-\/low T1 and 40 patients LVH+), and (ii) 40 patients with HCM. All patients underwent CMR. The LVH\u2009+\u2009FDc and the HCM groups were matched for age, sex, body surface area and left ventricular (LV) mass. The following AMVA were measured on cine images: papillary muscles (PMs) hypertrophy (maximal diameter (Dmax) of anterolateral (Al) and posteromedial (Pm) PM), apical displacement, anteriorization of Al PM and anterior mitral valve leaflet (AMVL) elongation. Reference values for defining AMVA were derived from a matched healthy control group (<jats:italic>n<\/jats:italic>\u2009=\u200940).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both HCM and FDc LVH\u2009+\u2009patients showed PMs hypertrophy, with a greater degree in the FDc LVH\u2009+\u2009group [Dmax Al PM 16\u2009\u00b1\u20093.4 vs. 15\u2009\u00b1\u20093.1 mm, <jats:italic>p<\/jats:italic>\u20090.017; Dmax Pm PM 14\u2009\u00b1\u20094.0 vs.12 mm (10.0\u201314.0), <jats:italic>p<\/jats:italic>\u20090.039] As compared to controls, both HCM and FDc LVH\u2009+\u2009patients showed PMs apical displacement (HCM 83% vs. healthy volunteers 8%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001; FDc LVH\u2009+\u200965% vs. healthy volunteers 8%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), with a greater prevalence in HCM. Anteriorization of Al PM was only evident in HCM (15\u2009\u00b1\u20096.2 vs. healthy controls 21\u2009\u00b1\u20095.3\u2005mm, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Elongation of AMVL was detected both in HCM and FDc with LVH\u2009+\u2009(HCM 29\u2009\u00b1\u20094.0 vs. healthy volunteers 24\u2009\u00b1\u20092.9\u2005mm, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001; FDc LVH\u2009+\u200927\u2009\u00b1\u20094.0 vs. healthy volunteers 24\u2009\u00b1\u20092.9\u2005mm, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) without significant differences between the two phenocopies. The prevalence of myocardial crypts was higher among HCM patients than in FDc LVH\u2009+\u2009patients (75% vs. 48%, <jats:italic>p<\/jats:italic> 0.012).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>we report greater PMs hypertrophy in FDc and a higher prevalence of PMs positional alterations (anterior and apical displacement) and myocardial crypts in HCM. All these AMVA became more pronounced with the progression of the FDc phenotype. We suggest the systematic inclusion of the analysis of AMVA by simple linear measurements on cine images in the CMR assessment of hypertrophic cardiomyopathies, to help in the differential diagnosis between HCM and FDc and to facilitate early detection of cardiac involvement in FDc.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1458705","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:37:04Z","timestamp":1727671024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular magnetic resonance insights into anomalies of the mitral valve apparatus in Fabry cardiomyopathy and hypertrophic cardiomyopathy"],"prefix":"10.3389","volume":"11","author":[{"given":"Lara","family":"Tondi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Disabato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"D\u2019Andria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"De Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Canepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Carrafiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Camporeale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/HCO.0000000000000200","article-title":"Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy","volume":"30","author":"Teo","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s12265-011-9319-6","article-title":"The mitral valve in hypertrophic cardiomyopathy: old versus new concepts","volume":"4","author":"Hag\u00e8ge","year":"2011","journal-title":"J Cardiovasc Transl Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.110.985812","article-title":"Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy","volume":"124","author":"Maron","year":"2011","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/ehjci\/jey095","article-title":"Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers","volume":"19","author":"Groarke","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/CIRCIMAGING.114.002411","article-title":"Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy","volume":"7","author":"Captur","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12968-015-0114-4","article-title":"A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease","volume":"17","author":"Kozor","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ehjci\/jew187","article-title":"Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping","volume":"18","author":"Kozor","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e007168","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Cardiac phenotype of prehypertrophic Fabry disease","volume":"11","author":"Nordin","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/ehjci\/jey132","article-title":"Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets","volume":"19","author":"Militaru","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"22","author":"Kawel-Boehm","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"ESC Scientific document group. 2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.jcmg.2021.03.032","article-title":"Maximal wall thickness measurement in hypertrophic cardiomyopathy: biomarker variability and its impact on clinical care","volume":"14","author":"Captur","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/ehjci\/jead078","article-title":"Apical papillary muscle displacement is a prevalent feature and a phenotypic precursor of apical hypertrophic cardiomyopathy","volume":"24","author":"Filomena","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13244-019-0761-3","article-title":"Magnetic resonance imaging of the papillary muscles of the left ventricle: normal anatomy, variants, and abnormalities","volume":"10","author":"Rajiah","year":"2019","journal-title":"Insights Imaging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"B20","doi-asserted-by":"publisher","first-page":"27714","DOI":"10.1038\/srep27714","article-title":"The embryological basis of subclinical hypertrophic cardiomyopathy","volume":"6","author":"Captur","year":"2016","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.31083\/j.rcm2305177","article-title":"Cardiac magnetic resonance features of Fabry disease: from early diagnosis to prognostic stratification","volume":"23","author":"Camporeale","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/ehjci\/jes035","article-title":"Myocardial crypts in hypertrophic cardiomyopathy: the new gang in town","volume":"13","author":"Rowin","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"B25","doi-asserted-by":"publisher","first-page":"131357","DOI":"10.1016\/j.ijcard.2023.131357","article-title":"Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: a CMR-based head-to-head comparison and outcome analysis","volume":"393","author":"Moroni","year":"2023","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e008424","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2021.07.022","article-title":"ECG-based score estimates the probability to detect Fabry disease cardiac involvement","volume":"339","author":"Figliozzi","year":"2021","journal-title":"Int J Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","article-title":"Atrial dysfunction assessed by cardiac magnetic resonance as an early marker of Fabry cardiomyopathy","volume":"13","author":"Bernardini","year":"","journal-title":"JACC Cardiovasc Imaging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/ehjci\/jeaa354","article-title":"Trabecular complexity as an early marker of cardiac involvement in Fabry disease","volume":"23","author":"Camporeale","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12872-023-03463-w","article-title":"Prevalence of papillary muscle hypertrophy in Fabry disease","volume":"23","author":"Cianciulli","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2022.06.022","article-title":"Validated model for prediction of adverse cardiac outcome in patients with Fabry disease","volume":"80","author":"Orsborne","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.14744\/AnatolJCardiol.2022.2503","article-title":"The frequency of Fabry disease in patients with cardiac hypertrophy of Various phenotypes including prominent papillary muscle: the TUCARFAB study in Turkey","volume":"27","author":"\u00d6zpelit","year":"","journal-title":"Anatol J Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1458705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:38:08Z","timestamp":1727789888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1458705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":34,"alternative-id":["10.3389\/fcvm.2024.1458705"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1458705","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1458705"}}